Alnylam Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to the development and commercialization of innovative therapeutics based on RNA interference. The company's portfolio includes treatments for rare genetic conditions, such as hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, among others. Alnylam is also exploring treatments for a variety of other diseases, including hemophilia, hypercholesterolemia, and Alzheimer’s disease. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has formed strategic partnerships with several leading pharmaceutical companies to advance its mission of transforming scientific discoveries into breakthrough therapies.
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech…
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, “Fool me once, shame on you; fool me twice, shame on me.”…
Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto Networks.
Tuesday's top analyst upgrades and downgrades included Advance Auto Parts, Alphabet, Biogen, Cheesecake Factory, Chesapeake Energy, Micron Technology, MongoDB, Ross Stores, Tesla and TG Therapeutics.
Monday's top analyst upgrades and downgrades included Apple, Atlassian, Block, CF Industries, Comerica, DraftKings, Exact Sciences, Global Payments, Kellogg, Mobileye Global, Shopify, VFC and Zions Bancorp.
Monday's top analyst upgrades and downgrades included Adobe, Carvana, Goldman Sachs, Hudson Pacific Properties, Moderna, Take-Two Interactive Software and T-Mobile.
Wednesday's top analyst upgrades and downgrades included Block, Boeing, Cemex, Constellation Brands, FirstEnergy, Freeport-McMoRan, GoodRx, Hasbro, Kosmos Energy, PayPal, Shopify, Starbucks, Toast and Williams-Sonoma.
Thursday's top analyst upgrades and downgrades included Adobe, Carnival, Hyatt Hotels, Nio, Nvidia, RealReal, Starbucks, Tyson Foods and Vertex Pharmaceuticals.
Friday's top analyst upgrades and downgrades included Agnico-Eagle Mines, Biogen, Exelon, Meta Platforms, New York Times, PulteGroup, Snap and Vertex Pharmaceutical.
Monday afternoon's top analyst upgrades and downgrades included JetBlue Airways, Rocket Companies, Ross Stores, Sea, Southwest Airlines, Spirit Airlines, United Airlines, U.S. Bancorp and Wells Fargo.
Tuesday afternoon's top analyst upgrades and downgrades included EVgo, Luminar Technologies, Tencent Music Entertainment and Tesla.
Monday afternoon's analyst upgrades and downgrades included Activision Blizzard, BioMarin, eBay and Teladoc.
Monday's top analyst upgrades and downgrades included Akamai Technology, ContextLogic, DuPont de Nemours, First Solar, Peabody Energy, Southwest Airlines, 3M and Union Pacific.
